Hypertension Unit, Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil.
Hypertension Unit, Renal Division, University of Sao Paulo, Sao Paulo, Brazil.
J Clin Sleep Med. 2021 Apr 1;17(4):703-709. doi: 10.5664/jcsm.9008.
Minimal focus has been placed on variations in health care delivery for obstructive sleep apnea (OSA). This study compared positive airway pressure usage in developing countries (Brazil and Mexico) vs. a developed country (United States) and investigated the impact of a patient engagement tool (myAir; ResMed, San Diego, CA) on adherence.
Deidentified data from the AirView database (ResMed) for patients receiving positive airway pressure therapy with wirelessly connected Air10 (AirSense and AirCurve) devices in Brazil, Mexico, and the United States were analyzed. Adherence was defined using US Center for Medicare and Medicaid Services (CMS) criteria (usage ≥ 4 h/night on ≥ 70% of nights in the first 90 days).
The analysis included 4,181,490 patients (Brazil: 31,672; Mexico 16,934; United States: 4,132,884). CMS adherence over 90 days was slightly lower in Latin America vs. the United States (Brazil: 71.7%; Mexico: 66.4%; United States: 74.0%). Significantly fewer patients were using the patient engagement tool in Brazil (8.1%) and Mexico (2.8%) vs. the United States (26%; both P < .001). Patients registered to use an engagement tool had a higher rate of CMS adherence and were twice as likely to achieve CMS adherence. Average daily usage and days with usage > 4 hours in the first week were the strongest predictors of CMS adherence. Across all countries, > 80% of patients meeting CMS criteria at 3 months were still using positive airway pressure therapy at 1 year, with 1-year adherences rates of > 75%.
Short-term and long-term positive airway pressure adherence rates in Brazil and Mexico were similar to those achieved in the United States. Patients who registered to use an engagement tool consistently had better adherence than those who did not.
阻塞性睡眠呼吸暂停(OSA)的医疗保健服务提供方面存在很大差异,但这方面的研究却很少。本研究比较了发展中国家(巴西和墨西哥)与发达国家(美国)之间的正压通气使用情况,并研究了患者参与工具(myAir;ResMed,圣地亚哥,CA)对依从性的影响。
分析了来自 ResMed 的 AirView 数据库(AirView 数据库)中使用具有无线连接的 Air10(AirSense 和 AirCurve)设备接受正压通气治疗的患者数据,这些患者分别来自巴西、墨西哥和美国。依从性使用美国医疗保险和医疗补助服务中心(CMS)标准定义(在最初 90 天内,每晚使用≥4 小时且≥70%的夜晚)。
分析共纳入 4181490 名患者(巴西:31672 名;墨西哥 16934 名;美国:4132884 名)。90 天内 CMS 依从性在拉丁美洲略低于美国(巴西:71.7%;墨西哥:66.4%;美国:74.0%)。在巴西(8.1%)和墨西哥(2.8%)使用患者参与工具的患者明显少于美国(26%;均<0.001)。注册使用参与工具的患者 CMS 依从性更高,达到 CMS 依从性的可能性是未注册患者的两倍。在第一周内平均每天使用和使用>4 小时的天数是 CMS 依从性的最强预测因素。在所有国家中,超过 80%的符合 CMS 标准的患者在 3 个月时仍在使用正压通气治疗,1 年后的依从率>75%。
巴西和墨西哥的短期和长期正压通气依从率与美国相似。注册使用参与工具的患者的依从性始终优于未注册患者。